Haleon PLC Sponsored ADR (NYSE:HLN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Haleon has a “Moderate Buy” consensus from nine analysts: two rate it a buy, two a strong buy, four a hold, and one a sell.
• HLN shares rose 3.5% to $10.38, trading between a 52-week range of $8.65 and $11.28. Institutional investors and hedge funds own 6.67% of the company.
• Haleon reduced its dividend to $0.0642 per share from $0.1307, with a reported payout ratio of 30.77%.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, two have issued a buy recommendation and two have given a strong buy recommendation to the company.

Several brokerages have recently issued reports on HLN. Royal Bank Of Canada reissued a "sector perform" rating on shares of Haleon in a report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Haleon in a research note on Wednesday, September 23rd. Morgan Stanley reiterated an "overweight" rating on shares of Haleon in a research report on Thursday, August 6th. Zacks Research raised shares of Haleon from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Haleon in a research note on Friday, September 25th.

Institutional Trading of Haleon

Several institutional investors have recently modified their holdings of HLN. Root Financial Partners LLC acquired a new position in shares of Haleon during the 3rd quarter worth about $25,000. Western Wealth Management LLC purchased a new position in Haleon in the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company's stock worth $30,000 after buying an additional 2,404 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company's stock worth $58,000 after buying an additional 1,055 shares during the last quarter. Finally, Fiduciary Financial Group LLC acquired a new stake in Haleon in the 2nd quarter worth about $97,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Trading Up 3.5%

Shares of NYSE:HLN opened at $10.38 on Friday. Haleon has a 52-week low of $8.65 and a 52-week high of $11.28. The business has a 50-day moving average price of $9.55 and a 200-day moving average price of $9.51. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The stock has a market cap of $45.69 billion, a price-to-earnings ratio of 26.60, a PEG ratio of 2.26 and a beta of 0.14.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which was paid on Thursday, September 17th. Shareholders of record on Friday, August 14th were issued a dividend of $0.0642 per share. The ex-dividend date of this dividend was Friday, August 14th. This is a negative change from Haleon's previous dividend of $0.1307. This represents a yield of 132.0%. Haleon's payout ratio is 30.77%.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company's products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.